Natera Collaborates With Kupando Therapeutics to Monitor Molecular Response in Phase 1 Trial of Novel Immunotherapy KUP-101
Natera, Inc., a global leader in cell-free DNA analysis and precision medicine, has announced a new collaboration with Kupando Therapeutics to support a Phase 1 clinical trial evaluating the company’s lead immunotherapy candidate, KUP-101. The clinical study, sponsored by Kupando Therapeutics, will incorporate Natera’s Latitude tissue-free assay for molecular residual disease (MRD) detection) to monitor treatment response through serial measurements of circulating tumor DNA (ctDNA).
The collaboration brings together Natera’s expertise in advanced cell-free DNA testing and Kupando’s novel approach to cancer immunotherapy. By incorporating longitudinal ctDNA analysis into the clinical trial, researchers aim to gain additional molecular insights into how patients respond to KUP-101 over the course of treatment.
The Phase 1 trial will enroll patients with advanced tumors across multiple types of skin cancer. Participants will receive treatment with KUP-101, while Latitude MRD testing will be conducted at multiple timepoints throughout the study. This repeated testing is designed to track changes in ctDNA and provide researchers with information about molecular response dynamics as treatment progresses.
The first patient has successfully received a dose of KUP-101, marking an important milestone for Kupando’s clinical development program. Following the initial dosing, the trial’s safety committee approved continued enrollment of additional patients across activated clinical sites. These sites include leading oncology centers in Germany, supporting the expansion of the study and further evaluation of the investigational therapy.
Advancing a Novel Approach to Cancer Immunotherapy
KUP-101 is being developed as an innovative immunotherapy designed to activate the body’s innate immune system and induce a biological process known as trained immunity. Unlike conventional approaches that primarily focus on directly targeting cancer cells or stimulating specific components of the adaptive immune system, KUP-101 is intended to harness innate immune mechanisms as a potential strategy for treating difficult-to-treat cancers.
The investigational therapy is being explored as a potentially tissue-agnostic treatment, meaning that its therapeutic potential could extend across different solid tumor types rather than being limited to a single cancer originating in one specific tissue.
Kupando is evaluating KUP-101 both as a standalone treatment and potentially in combination with other therapeutic agents. The company’s strategy reflects the growing interest in approaches that can stimulate broader immune responses against cancer and potentially address tumors that have proven difficult to treat with existing therapies.
Because KUP-101 represents a novel mechanism of action, understanding how the drug affects tumors at the molecular level will be an important component of its clinical development. Monitoring ctDNA over time can provide researchers with an additional method for evaluating molecular changes associated with treatment.
Role of Natera’s Latitude Assay
Natera’s Latitude assay is being incorporated into the Phase 1 study to assess molecular response through serial ctDNA measurements. Cell-free DNA is released into the bloodstream by cells throughout the body, and tumor-derived fragments can provide information about the presence and activity of cancer.
In oncology research, ctDNA analysis has become an increasingly important tool for studying tumor dynamics. Changes in the amount of tumor-derived DNA detected in blood samples may provide indications of how a tumor is responding to treatment, potentially complementing conventional clinical and imaging assessments.
For a novel immunotherapy such as KUP-101, serial molecular monitoring may provide particularly valuable information because treatment response can involve complex biological changes within the tumor and immune system.
The use of Latitude at multiple timepoints will allow researchers to examine ctDNA dynamics during treatment rather than relying on a single measurement. This longitudinal approach could help investigators better understand the timing and extent of molecular changes associated with KUP-101 administration.
The information generated through the study may also contribute to future clinical development decisions as Kupando evaluates the potential of KUP-101 in advanced solid tumors.
First Patient Dosing Marks Clinical Development Milestone
The successful dosing of the first patient represents a significant milestone for Kupando Therapeutics. It moves KUP-101 from earlier-stage development into clinical evaluation and begins the process of generating human safety and treatment-response data for the investigational therapy.
Following review by the trial’s safety committee, enrollment has been authorized to continue across activated clinical sites. The involvement of oncology centers in Germany provides access to specialized clinical expertise and patient populations relevant to the study.
Johanna Holldack, M.D., founder and chief executive officer of Kupando Therapeutics, described the first patient dosing milestone as an important inflection point for the company.
According to Holldack, KUP-101 represents a fundamentally different strategy for addressing difficult-to-treat cancers by combining innate immune stimulation with the induction of trained immunity. She also highlighted the potential role of Natera’s Latitude assay in providing information about treatment-response dynamics.
By tracking molecular activity during the study, the company expects the ctDNA data to help researchers understand the biological effects of KUP-101 and potentially identify patterns that could inform future development.
Potential Across Multiple Solid Tumor Types
One of the distinguishing features of KUP-101’s development strategy is its potential application across multiple solid tumors. The current Phase 1 study is focused on patients with advanced tumors involving multiple types of skin cancer, but the underlying therapeutic concept is intended to have broader applicability.
The development of tissue-agnostic cancer therapies has become an important area of research as scientists seek treatments that are based on biological characteristics rather than solely on the anatomical location of a tumor.
If KUP-101 demonstrates promising safety and biological activity in early clinical development, the approach could potentially be evaluated in additional solid tumor settings. The current trial is therefore expected to provide important early information about the therapeutic’s safety profile, biological activity, and potential molecular response patterns.
However, as an investigational therapy, KUP-101 will require further clinical evaluation to determine its safety, efficacy, optimal dosing, and potential role in cancer treatment.
Importance of Molecular Monitoring in Drug Development
The integration of ctDNA testing into clinical trials reflects a broader shift toward incorporating molecular biomarkers into oncology research. Traditional assessments of treatment response can include radiographic imaging, physical examinations, laboratory measurements, and clinical outcomes. Molecular testing can provide another layer of information by examining biological changes that may occur before or alongside visible changes in tumors.
For emerging therapies, these molecular insights may be particularly useful during early-stage trials. Researchers can potentially use biomarker data to characterize treatment activity, explore response patterns, and generate hypotheses for subsequent studies.
In the case of KUP-101, serial ctDNA measurements could help investigators examine whether molecular changes correlate with treatment exposure and clinical observations. The information may ultimately contribute to a more comprehensive understanding of how the therapy interacts with tumors and the immune system.
Eric Matthews, general manager of biopharma at Natera, said the company is pleased to collaborate with Kupando as it advances its approach to innate immune activation. He highlighted Latitude’s ability to evaluate ctDNA dynamics across different solid tumor types as an important feature of the collaboration.
Natera expects the molecular data generated during the trial to provide insights that can support Kupando’s ongoing development program.
Supporting the Next Stage of KUP-101 Development
The collaboration between Natera and Kupando Therapeutics demonstrates the increasing role of precision molecular monitoring in the development of next-generation cancer therapies. As investigators evaluate novel mechanisms such as innate immune activation and trained immunity, understanding molecular response may provide valuable context alongside traditional clinical measurements.
Through the use of Latitude testing, Kupando’s Phase 1 trial will collect longitudinal ctDNA data from patients receiving KUP-101. The resulting information may help researchers assess molecular changes during therapy and develop a clearer picture of the investigational treatment’s biological activity.
The trial’s continued enrollment following first-patient dosing represents the next stage of KUP-101’s clinical evaluation. As additional patients are treated at participating centers, the study is expected to generate further safety and molecular-response information.
For Natera, the collaboration further expands the company’s involvement in biopharmaceutical clinical development and demonstrates the potential application of cell-free DNA technologies across diverse oncology programs.
For Kupando, integrating molecular response monitoring into the clinical development of KUP-101 could provide an additional source of evidence as the company evaluates its first-in-class approach to innate immune stimulation.
Ultimately, the Phase 1 trial will be important in determining whether KUP-101 can safely and effectively activate immune mechanisms against advanced cancers. While substantial clinical investigation remains ahead, the combination of an innovative immunotherapy approach with longitudinal ctDNA monitoring provides researchers with an opportunity to examine both clinical and molecular responses as the program progresses.
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.